<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html lang="en">
<head><meta http-equiv="Content-Type" content="text/html; charset=">
<title>Handoff Notes and Reminders
</title>
</head>

<body >


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><img height="51" width="199" src="Cardio%20SPT%20%20Kakkar%20239054-29%20v400.jpg" 	alt="Cardio%20SPT%20%20Kakkar%20239054-29%20v400.jpg" border="0" ></p>
</td>
<td><p><strong>Production Ticket</strong></p>
</td>
</tr>

</table>
<p></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Who?</strong></p>
</td>
<td><p><strong>When?</strong></p>
</td>
<td><p><strong>What?</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>M Felton</p>
</td>
<td><p>5/22/18</p>
</td>
<td><p>initiate</p>
</td>
</tr>

<tr valign="top">
<td><p>C Padbury</p>
</td>
<td><p>8/1</p>
</td>
<td><p>Content</p>
</td>
</tr>

<tr valign="top">
<td><p>J Habib</p>
</td>
<td><p>8/15/18</p>
</td>
<td><p>Outcomes Review</p>
</td>
</tr>

<tr valign="top">
<td><p>D Frassetto</p>
</td>
<td><p>8/23/18</p>
</td>
<td><p>Copyedit</p>
</td>
</tr>

<tr valign="top">
<td><p>N Zawahir</p>
</td>
<td><p>8/30/18</p>
</td>
<td><p>CME Review</p>
</td>
</tr>

<tr valign="top">
<td><p>E Casey</p>
</td>
<td><p>8/30/18</p>
</td>
<td><p>Registered for ABIM MOC</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>
<p>Click <strong>+</strong> to add another table row</p>

<p>&#953; = additional instructions available when you hover cursor over; <strong>Bold text</strong> = questions to be answered</p>
<h1>
<a name="HandoffNotes"></a><a name="Heading31"></a><strong>Handoff Notes and Reminders</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>To Scientific Directors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Copyeditors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Production/Studio &#953;</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To CME Department</strong></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="Heading40"></a><strong>General Information</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Activity SF#(s):</strong></p>
</td>
<td><p>239054.29</p>
</td>
<td><p><strong>Related SF#s &#953;:</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Supporter(s):</strong></p>
</td>
<td><p>Bayer AG</p>
</td>
<td><p><strong>Partner (s):</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Product type:</strong></p>
</td>
<td><p>Spotlight</p>
</td>
<td><p><strong>If live event, enter date:</strong></p>
</td>
<td><p>(Click to enter date...)</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td><p><strong>IME program?</strong></p>
</td>
<td><p>&#9746; No   &#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Outcomes Study included? &#953;</strong></p>
</td>
<td><p>&#9744; No</p>
</td>
<td><p>&#9746; Yes; <strong>measurement focus:</strong> </p>
</td>
<td><p>&#9746; Competence     &#9744; Performance    &#9744;Patient Outcomes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Geotargets &#953;</strong></p>
</td>
<td><p><strong>1:</strong> Global</p>
</td>
<td><p><strong>2:</strong> (Choose a geotarget...)</p>
</td>
<td><p><strong>3:</strong> (Choose a geotarget...)</p>
</td>
<td><p><strong>4:</strong> (Choose a geotarget...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Select one supporter attribution:</strong></p>

<p>&#9746; One Supporter</p>

<p>&#9744; Multi-Support</p>

<p>&#9744; Medscape-supported activity: Developed and funded by Medscape</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Type of badge:</strong></p>
</td>
<td><p>&#9746; Text only</p>
</td>
<td><p>&#9744; Supporter logo</p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p>Paste badge(s) here: <img height="69" width="297" src="Cardio%20SPT%20%20Kakkar%20239054-29%20v401.jpg" 	alt="C:\Users\mchevry\Box Sync\Documents\US Supporter Badges\Bayer AG.gif" border="0" ></p>
</td>
</tr>

</table>
<h1>
<a name="Heading75"></a><strong>Course/CME Details</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Title: &#953;</strong></p>
</td>
<td><p>Cancer&#8208;Associated Thrombosis: Emerging Concepts and Paradigms</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Teaser: &#953;</strong></p>
</td>
<td><p>Drs Kakkar, Khorana, and Weitz discuss the challenge of identifying and treating patients with cancer at risk for VTE.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Faculty/Author(s) Byline(s): &#953;</strong></p>
</td>
<td><p>Lord Ajay K. Kakkar, MD, PhD, FRCS, FRCP; Alok A. Khorana, MD; Jeffrey I. Weitz, MD, FRCP</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Indicate thumbnail URL &#953;:</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Target Audience:</strong></p>
</td>
<td><p>This activity is intended for cardiologists, hematologists/oncologists, and other healthcare professionals who treat patients with cancer.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Goal Statement: </strong></p>
</td>
<td><p>The goal of this activity is to provide an update on new treatment strategies for patients with cancer at risk for thromboembolism.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Peer review required?</strong></p>
</td>
<td><p>Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Educational Design &#953;</strong></p>
</td>
<td><p>&#9746; Competence &#953;</p>
</td>
<td><p>&#9744; Performance &#953;</p>
</td>
<td><p>&#9744; Patient Outcomes &#953;</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Core Competencies &#953;</strong></p>
</td>
<td><p>&#9744; Patient care and procedural skills</p>
</td>
<td><p>&#9746; Medical knowledge</p>
</td>
<td><p>&#9744; Practice-based learning and improvement </p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>&#9744; Interpersonal &amp; communication skills</p>
</td>
<td><p>&#9744; Professionalism</p>
</td>
<td><p>&#9744; Systems-based practice</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>IPCE Competencies &#953;</strong></p>
</td>
<td><p>&#9744; Interprofessional Education (IPCE)</p>
</td>
<td><p>&#9744; Roles and Responsibilities</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>&#9744; Interprofessional Communication</p>
</td>
<td><p>&#9744; Teamwork &#953;</p>
</td>
<td><p>&#9744; Values and Ethics</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Activity Length &#953;:</strong></p>
</td>
<td><p>27 min</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Credits Available &#953;:</strong></p>

<p>&#9746;<strong> Medscape Joint Accreditation Statement </strong></p>

<p>Direct Provider:</p>

<p>In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>

<p><img height="79" width="124" src="Cardio%20SPT%20%20Kakkar%20239054-29%20v402.jpg" 	alt="C:\Users\mchevry\Box Sync\Documents\US Supporter Badges\Bayer AG.gif" border="0" ></p>
</td>
</tr>

<tr valign="top">
<td><p>&#9746; <strong>ACCME:</strong> 0.50 AMA PRA Category 1&#8482; Credit:</p>

<p>For Physicians</p>

<p>Medscape, LLC designates this enduring material for a maximum of 0.50 <strong><em>AMA PRA Category 1 Credit(s)&#8482;</em></strong>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>ANCC:</strong> (Select credit hours...) contact hours (Select credit hours...) contact hours are in the area of pharmacology)</p>

<p>(Select...)</p>

<p>&#9746; <strong>ABIM MOC:  PARS Activity Identifier </strong>201126571</p>
</td>
</tr>

<tr valign="top">
<td><p>Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>ACPE:</strong> Knowledge-based (Select credit hours...) CEUs); Application-based (Select credit hours...) CEUs)</p>

<p>(Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>CPD:</strong> (Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>OUS Options:</strong> (Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>IME:</strong> (Select...)</p>
</td>
</tr>

<tr valign="top">
<td><p>&#9744; <strong>Other:</strong> (Click here to enter...)</p>
</td>
</tr>

</table>
<h1>


<a name="Heading134"></a><a name="Heading135"></a><strong>Partner Details</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Partner Statement:</strong></p>

<p><strong>(edit standard statement if needed)</strong></p>
</td>
<td><p>Developed through a partnership between Medscape and enter partner. </p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Partner source marker required?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; enter partner abbreviation here: (Click here to enter...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Partner logo required?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; paste logo here:</p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Required passing score:</strong></p>
</td>
<td>&nbsp;</td>
<td><p><strong>Evaluation required?</strong></p>
</td>
<td><p>&#9744; Yes     &#9744; No</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Copyright Statement:</strong></p>
</td>
<td><p>&#9746; &#169;2018 Medscape, LLC</p>
</td>
<td><p>&#9744; &#169;2018 WebMD Global, LLC</p>
</td>
<td><p>&#9744; &#169;2018 (Add Partner&#8217;s copyright statement...)</p>
</td>
</tr>

</table>
<h1>
<a name="Heading154"></a><strong>Collection Page Details</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Is there a collection page?</strong></p>
</td>
<td><p>&#9744; No</p>
</td>
<td><p>&#9746; Yes; <strong>what type?</strong> Clinical Advances; <strong>provide name and URL:</strong> https://www.medscape.org/sites/advances/anticoagulation-thrombosis</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>	If &#8216;Clinical Advances,&#8217; which bucket does the content go in?</strong> VTE</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Add to other publications or pages?</strong></p>
</td>
<td><p>&#9744; No</p>
</td>
<td><p>&#9746; Yes; add <strong>URL(s) and bucket name(s) &#953;</strong>: https://www.medscape.org/oncology</p>
</td>
</tr>

</table>
<h1>
<a name="Heading164"></a><strong>Product-Specific Information and Add-ons</strong></h1>
<p></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Is there an Outcomes study?</strong></p>
</td>
<td><p>Linked Learning Assessment (Medscape)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there a second Outcomes study?</strong></p>
</td>
<td><p>No</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there a Medscape Discuss or Discuss Lite?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Medscape Discuss</p>
</td>
<td><p>&#9744; Medscape Discuss Lite</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there an associated HCP Perspective?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is this program associated with a Patient Education Program or Destination Page?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Provide server path for Prescription to Learn PDF:</strong></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>


<a name="Heading182"></a><a name="Heading183"></a><strong>Learning Objectives and KMI Map</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Upon completion of this activity, participants will:</strong></p>
</td>
<td><p><strong>Question type assessing this objective</strong></p>
</td>
<td><p>Question #</p>
</td>
</tr>

<tr valign="top">
<td><p>Have increased knowledge regarding the</p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p>Latest data on use of non-vitamin K antagonist oral anticoagulants in the setting of cancer-associated thrombosis</p>
</td>
<td><p>Linked Pre-/Post-assessment</p>
</td>
<td><p>1,2</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p>Have greater competence related to</p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p>Risk assessment for venous thromboembolism (VTE) recurrence in patients with cancer</p>
</td>
<td><p>CME evaluation</p>
</td>
<td><p>1</p>
</td>
</tr>

<tr valign="top">
<td><p>Strategies to tailor long-term VTE treatment strategies in patients with cancer</p>
</td>
<td><p>Linked Pre-/Post-assessment</p>
</td>
<td><p>3</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>


<h1>
        <a name="Heading212"></a>Questions (Evaluations, Assessments, and Posttests)</h1>
        <p></p>
        

        <p>Question 1</p>
        
        <p>Question reporting priority: First</p>
        
        <p>Question must follow question # (optional):</p>
        
        <p>Question type: Pre/Post Assessment Question Pairs (LLA)</p>
        
        <p>Question Introduction (optional &#953;): The Hokusai VTE Cancer and SELECT-D trials were designed to test the use of edoxaban and rivaroxaban, respectively, in the <u>treatment</u> of cancer-associated thrombosis, after initial treatment with low-molecular-weight heparin (LMWH).</p>
        
        <p>Question: What doses of the drugs were chosen?</p>
        
        <p>Answer choices &#953;:</p>
        
        <p>&#8226;	Edoxaban 30 mg daily; rivaroxaban 20 mg once daily </p>
        
        <p>&#8226;	Edoxaban 60 mg daily; rivaroxaban 20 mg once daily</p>
        
        <p>&#8226;	Edoxaban 30 mg daily; rivaroxaban 10 mg twice daily for 3 weeks, then 15 mg once daily</p>
        
        <p>&#8226;	Edoxaban 60 mg daily; rivaroxaban 15 mg twice daily for 3 weeks, then 20 mg once daily</p>
        
        <p>Answer explanation: In the Hokusai VTE Cancer and SELECT-D trials the doses of the drugs chosen were edoxaban 60 mg daily; rivaroxaban 15 mg twice daily for 3 weeks, then 20 mg once daily.</p>
        


        <p>Question 2</p>
        
        <p>Question reporting priority: Second</p>
        
        <p>Question must follow question # 1:</p>
        
        <p>Question type: Pre/Post Assessment Question Pairs (LLA)</p>
        
        <p>Question Introduction (optional &#953;): The CASSINI and AVERT trials are designed to test the use of rivaroxaban and apixaban, respectively, in the <u>prevention</u> of cancer-associated thrombosis.</p>
        
        <p>Question 2: What doses of the drugs were chosen?</p>
        
        <p>Answer choices &#953;:</p>
        
        <p>&#8226;	Rivaroxaban 20 mg once daily; apixaban 5 mg twice daily</p>
        
        <p>&#8226;	Rivaroxaban 15 mg once daily; apixaban 5 mg twice daily</p>
        
        <p>&#8226;	Rivaroxaban 10 mg once daily; apixaban 2.5 mg twice daily</p>
        
        <p>&#8226;	Rivaroxaban 5 mg once daily; apixaban 2.5 mg twice daily</p>
        
        <p>Answer explanation: In the CASSINI and AVERT trials, doses of the drugs chosen were rivaroxaban 10 mg and apixaban 2.5 mg twice daily, respectively.</p>
        


        <p>Question 3</p>
        
        <p>Question reporting priority: Third</p>
        
        <p>Question must follow question # (optional):</p>
        
        <p>Question type: Pre/Post Assessment Question Pairs (LLA)</p>
        
        <p>Question Introduction (optional &#953;): In patients with newly diagnosed cancer who developed VTE, the Kaplan-Meier rate of persistence with LMWH was 37%.</p>
        
        <p>Question: What percentage of patients could be expected to remain on oral anticoagulation at 6 months? </p>
        
        <p>Answer choices &#953;:</p>
        
        <p>&#8226;	40%</p>
        
        <p>&#8226;	50%</p>
        
        <p>&#8226;	60%</p>
        
        <p>&#8226;	70%</p>
        
        <p>Answer explanation: A total of 2941 patients with newly diagnosed cancer who developed VTE and received anticoagulation in outpatient settings were identified. The Kaplan-Meier rate of persistence to both rivaroxaban and warfarin therapy at 6 months was 61%. </p>
        


        <p>Question 4</p>
        
        <p>Question reporting priority: Choose an item.</p>
        
        <p>Question must follow question # (optional):</p>
        
        <p>Question type: Pre/Post Assessment Question Pairs (LLA)</p>

        <p>Choose a building block.</p>

        <p>Question: How confident are you in treating patients with cancer who develop venous thromboembolism? (Select ranking from 1 [Not confident] to 5 [Very confident])</p>
        
        <p>Answer choices:</p>
        
        <p>&#8226;	1 - Not confident</p>
        
        <p>&#8226;	2</p>
        
        <p>&#8226;	3</p>
        
        <p>&#8226;	4</p>
        
        <p>&#8226;	5 &#8211; Very confident</p>
        


        <p>Question 5 (demographic)</p>
        
        <p>Question must follow question # (optional):</p>
        
        <p>Choose a building block.</p>

        <p>Show question in pre- or postassessment? Post assessment only</p>
        
        <p>Question: Please indicate your prior familiarity with the subject matter. What percentage of this program's content was new to you?</p>
        
        <p>&#8226;	0%</p>
        
        <p>&#8226;	1%-24%</p>
        
        <p>&#8226;	25%-49%</p>
        
        <p>&#8226;	50%-74%</p>
        
        <p>&#8226;	75%-99%</p>
        
        <p>&#8226;	100%</p>
        
        

        <p>Question type: CME Posttest</p>
        
        <p>Question Introduction (optional &#953;): </p>
        
        <p>Question 1: Which of the following statements is true?</p>
        
        <p>Answer choices &#953;:</p>
        
        <p>&#8226;	A woman with breast cancer would have the same risk of thrombosis as a woman with lung cancer</p>
        
        <p>&#8226;	Gastrointestinal (GI) cancers put patients at particularly high risk of thrombosis</p>
        
        <p>&#8226;	 A history of venous thromboembolism (VTE) does not predict a higher risk for VTE </p>
        
        <p>&#8226;	Men are more at risk for cancer-associated thrombosis than women</p>
        
        <p>&#8226;	Answer explanation: Patients with GI cancer, particularly upper GI cancers, esophageal cancer, gastric cancer, and cancer within the lumen of the GI tract, are at a particularly high risk of thrombosis. According to the Ottawa Risk Score, a woman with breast cancer would have a higher risk of thrombosis than a woman with lung cancer. A history of VTE does predict a higher risk for VTE. According to the Ottawa risk score, women are more at risk for cancer-associated thrombosis than men.</p>


<h1>
<a name="Heading320"></a><strong>Content</strong></h1>
<p><strong>&lt;&lt;level 1&gt;&gt; Educational Impact Challenge</strong></p>

<p>The goal of this activity is to provide an update on new treatment strategies for patients with cancer at risk for thromboembolism.</p>

<p>Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.</p>

<p>&lt;&lt;Insert pre-assessment questions 1-4&gt;&gt;</p>

<p><strong>&lt;&lt;insert slide 1   (00:00) chapter title:  Introduction   &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;</strong> <strong>Cancer-Associated Thrombosis: Emerging Concepts and Paradigms</strong></p>
<p><strong>&lt;&lt;insert slide 2  (00:17) chapter title:   &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;</strong> Panelists</p>
<p><strong>&lt;&lt;insert slide 3  (00:57) chapter title:  Who Is at Risk?   &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt; Cancer-Associated Thrombosis: Who Is at Risk?</strong></p>

<p>&#8226;	Separating cancer into subcategories of patients who can or are likely to get blood clots vs those who are not likely to get blood clots is key</p>

<p>&#8226;	A single risk factor does not predict the full assessment of risk in this population </p>
<p></p>

<p><strong>&lt;&lt;insert slide 4  (02:38) chapter title:     &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;Cancer-Associated Thrombosis: <em>How to Identify Those at Risk <sup>[1]</sup></em></strong></p>

<p>&#8226;	Surveys suggest that cancer patients are very unware of the risk of venous thromboembolism (VTE)</p>

<p>&#8226;	They are very aware of becoming nauseated, having emesis, and getting infections and when to report these problems</p>

<p>&#8226;	They are not aware of leg swelling or increased shortness of breath or sudden onset of chest pain as being concerning</p>

<p>&#8226;	Providers must assess the risk, have a discussion, and educate patients about warning signs and symptoms of VTE </p>
<p><strong>&lt;&lt;insert slide 5   (03:22) chapter title: &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;</strong> <strong>Risk of VTE in Medical Patients<sup>[2]</sup></strong></p>
<p><strong>&lt;&lt;insert slide 6   (04:05) chapter title: CASSINI and AVERT   &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;Primary Prevention Trials<sup>[3,4]</sup></strong></p>

<p>&#8226;	Two studies that will be completed soon are looking at prophylaxis with either rivaroxaban 10 mg once a day vs placebo or apixaban 2.5 mg twice a day vs placebo</p>

<p>&#8226;	Both studies identify the highest risk patients </p>
<p><strong>&lt;&lt;insert slide 7  (05:06) chapter title:      &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;Bleeding Risk in Patients With Cancer</strong></p>
<p><strong>&lt;&lt;insert slide 8  (06:33) chapter title:      &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;Treating the Patient With VTE<sup>[1]</sup></strong></p>
<p><strong>&lt;&lt;insert slide 9  (07:42) chapter title:      &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;How Long to Treat?<sup>[1]</sup></strong></p>
<p></p>

<p><strong>&lt;&lt;insert slide 10    (08:24) chapter title: NOACs     &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt; NOACs vs LMWH In Patients With Cancer<sup>[5,6]</sup></strong></p>
<p><strong>&lt;&lt;insert slide 11 (08:45) chapter title: &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt; Study Results<sup>[5,6]</sup></strong></p>

<p>&#8226;	In both those trials, the non-vitamin K antagonist oral anticoagulants (NOACs) were better in terms of reducing the risk of recurrent VTE with some increase in bleeding</p>

<p>&#8226;	Both trials assessed the 6-month time point</p>

<p><tt>o	</tt>The Hokusai study extended to 12 months, but for most patients the median time was around 6 months </p>
<p></p>

<p><strong>&lt;&lt;insert slide 12  (09:24) chapter title: &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;LMWH and VKAs<sup>[7]</sup></strong></p>

<p>&#8226;	The advantage of low-molecular heparin vs vitamin K antagonist (VKA) is that you can titrate the dose </p>

<p>&#8226;	If, for example, a patient presents with gastrointestinal bleeding (GI), a lower dose can be used to start and then the dose can be gradually increased when bleeding ceases</p>

<p>&#8226;	Or, if a patient develops thrombocytopenia, you can titrate the dose down and ramp it back up again as the platelet count recovers</p>

<p>&#8226;	There is a flexibility in dosing, which is not seen with VKAs</p>

<p><tt>o	</tt>VKAs are only effective when the international normalized ratio (INR) is between 2 and 3, and that is difficult to maintain </p>
<p><strong>&lt;&lt;insert slide 13  (10:57) chapter title: &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;Study Results (cont)<sup>[5,6]</sup></strong></p>

<p>&#8226;	Hokusai VTE Cancer and SELECT-D studies had similar results</p>

<p>&#8226;	Bleeding was seen especially in patients with GI cancer </p>

<p>&#8226;	There are now broader options for anticoagulation to manage thrombosis in our cancer patients </p>
<p><strong>&lt;&lt;insert slide 14  (13:00) chapter title: &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt; Patient Persistence with Anticoagulant: <em>LMWH vs Oral Agents<sup>[8]</sup></em></strong></p>

<p>&#8226;	Consistently in studies looking at different populations -- older patients, younger patients, patients with private insurance, patients with Medicare -- the results are the same</p>

<p><tt>o	</tt>Persistence on low molecular weight heparin (LMWH) is much lower than persistence on any oral agent, including VKAs</p>

<p>&#8226;	There is clearly a limitation of prolonged parenteral therapy that needs to be borne in mind</p>

<p> </p>
<p><strong>&lt;&lt;insert slide 15 (14:28) chapter title: &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt; Challenges of Anticoagulation Therapy</strong></p>

<p>&#8226;	In the Hokusai VTE Cancer study, for example, only about 11% of the patients had hematological malignancies; thrombocytopenia was not a big issue</p>

<p>&#8226;	In patents with lymphoma or leukemia, thrombocytopenia becomes a major challenge </p>

<p>&#8226;	If anticoagulants are stopped, the risk of reoccurrence is at least around 20% in that first year<sup>[9]</sup></p>
<p><strong>&lt;&lt;insert slide 16  (18:21) chapter title: Ottawa Score&gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt; Ottawa Risk Score<sup>[10]</sup></strong></p>

<p>&#8226;	The Ottawa score has not been validated in every study</p>

<p>&#8226;	It is very good at predicting low-risk patients, but not so good at predicting high-risk patients </p>

<p>&#8226;	The other challenge is all of these risk assessment tools were developed in the LMWH era</p>

<p> </p>

<p><strong>&lt;&lt;insert slide 17  (19:12) chapter title: &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Tailoring Treatment</strong></p>
<p><strong>&lt;&lt;insert slide 18  (21:14) chapter title: &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt; ISTH Guidance Statement<sup>[11]</sup></strong></p>

<p>&#8226;	The term <em>suggest</em> has a specific meaning in the guidelines</p>

<p>&#8226;	The Hokusai VTE Cancer study carefully captured the different chemotherapeutic or biological agents being used by patients</p>

<p><tt>o	</tt>A wide array of different agents was used, and there did not seem to be a problem with them </p>
<p><strong>&lt;&lt;insert slide 19   (23:49) chapter title: CARAVAGGIO&gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;CARAVAGGIO<sup>[12]</sup></strong></p>
<p><strong>&lt;&lt;insert slide 20   (24:25) chapter title: Managing Anticoagulation&gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt; Managing Anticoagulation</strong></p>

<p>&#8226;	New International Society on Thrombosis and Haemostasis (ISTH) guidelines recommend taking patient preferences and values into account and having an informed discussion about the risk of bleeding and risk of recurrent VTE</p>
<p></p>

<p><strong>&lt;&lt;insert slide 21   (25:23) chapter title: Managing Anticoagulation&gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt; Managing Anticoagulation (cont)</strong></p>

<p><strong>&lt;&lt;insert slide 22    (25:56) chapter title: Summary  &gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Summary </strong></p>
<p><strong>&lt;&lt;insert slide 23  (26:34) chapter title:     &gt;&gt;</strong></p>
<p><strong>&lt;&lt;level 2&gt;&gt;Thank you</strong></p>

<p> <em>This content has been condensed for improved clarity.</em></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p>&lt;&lt;end slides&gt;&gt;</p>

<p>&lt;&lt;level 1&gt;&gt; Educational Impact Challenge</p>

<p>What did you learn from this activity? Please click on the &#8220;Next&#8221; button to proceed to a brief survey to see how your knowledge improved after the education. You can also see how your answers compare with those of your peers.</p>

<p>&lt;&lt;Note to Production: Insert page break between preamble and post-assessment questions&gt;&gt; </p>

<p>&lt;&lt;Note to production: Place post-assessment questions 1-5 (selected from the preassessment/intra-activity questions) here&gt;&gt;</p>
</td>
</tr>

</table>
<h1>
<a name="Heading434"></a><strong>Abbreviations</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p></p>

<p>CI = confidence interval</p>

<p>DVT = deep venous thrombosis</p>

<p>EGF = epidermal growth factor</p>

<p>GI = gastrointestinal</p>

<p>HR = hazard ratio</p>

<p>INR = international normalized ratio</p>

<p>ISTH = International Society on Thrombosis and Haemostasis</p>

<p>K-M = Kaplan-Meier</p>

<p>LMWH = low-molecular-weight heparin</p>

<p>NOAC = non-vitamin K antagonist oral anticoagulant</p>

<p>PE = pulmonary embolism</p>

<p>SC = subcutaneous</p>

<p>VEGF = vascular endothelial growth factor</p>

<p>VKA = vitamin K antagonist</p>

<p>VTE = venous thromboembolism</p>
</td>
</tr>

</table>
<h1>
<a name="Heading452"></a><strong>Additional Resources</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><em>Add additional resources below. NOTE: If a <strong>custom downloadable slide kit or custom downloadable PDF</strong> was sold above the </em><strong><em>standard decks</em> &#953;</strong><em> and resources that come with certain activities, it should be noted in the </em><a href="Cardio%20SPT%20%20Kakkar%20239054-29%20v4.html#HandoffNotes">HANDOFF NOTES AND REMINDERS</a><em> section above (include the custom label for document as well). <strong>Do not indicate here.</strong></em></p>
</td>
</tr>

</table>
<h1>
<a name="Heading455"></a><strong>Related Links</strong></h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p>CLINICAL ADVANCES IN Anticoagulation Management and Vascular Protection  <a href="https://www.medscape.org/sites/advances/anticoagulation-thrombosis">https://www.medscape.org/sites/advances/anticoagulation-thrombosis</a></p>

<p>Thrombosis, Cancer, and NOACs: A New Triad in the Making  <a href="https://www.medscape.org/viewarticle/890049">https://www.medscape.org/viewarticle/890049</a></p>

<p>Thrombosis TV: Treatment Across the Spectrum of Thromboembolic Disease <a href="https://www.medscape.org/sites/tv/thrombosis-tv">https://www.medscape.org/sites/tv/thrombosis-tv</a></p>
</td>
</tr>

</table>
<h1>
<a name="Heading460"></a><strong>Disclosures</strong></h1>
<h2>
<a name="Heading461"></a><strong>Faculty Information and Disclosure Statements</strong></h2>
<p><strong><em>Reminder: Complete the COI statements in the Work Front Custom Form prior to sending this document to CME Review</em></strong></p>

<p><strong><em>List in order as to appear on the site; include &#8220;host,&#8221; &#8220;moderator,&#8221; &#8220;panelists,&#8221; or other type of faculty designation when applicable</em></strong></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td>
<p>Moderator</p>

<p>Lord Ajay K. Kakkar, MD, PhD</p>

<p>Professor of Surgery</p>

<p>University College London</p>

<p>London, United Kingdom</p>

<p>Disclosure: Lord Ajay K. Kakkar, MD, PhD,  has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; Sanofi; Verseon</p>

<p>&#9746; Received grants for clinical research from: Bayer HealthCare</p>

<p>Dr Kakkar does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.</p>

<p>Dr Kakkar does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>

<p>Panelists</p>

<p>Alok A. Khorana, MD</p>

<p>Professor of Medicine </p>

<p>Cleveland Clinic Lerner College of Medicine</p>

<p>Case Western Reserve University Sondra and Stephen Hardis Chair in Oncology Research</p>

<p>Vice Chair (Clinical Services)</p>

<p>Director</p>

<p>GI Malignancies Program</p>

<p>Taussig Cancer Institute</p>

<p>Cleveland Clinic</p>

<p>Cleveland, Ohio, United States</p>

<p>Disclosure: Alok A. Khorana, MD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: AngioDynamics, Inc; Bayer HealthCare; Halozyme Therapeutics; Janssen Pharmaceuticals; Pfizer Inc.</p>

<p>&#9746; Received grants for clinical research from: Amgen</p>

<p>Dr Khorana does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.</p>

<p>Dr Khorana does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>

<p>Jeffrey I. Weitz, MD, FRCP</p>

<p>Professor of Medicine and Biochemistry</p>

<p>McMaster University</p>

<p>Hamilton, Ontario, Canada</p>

<p>Disclosure: Jeffrey I. Weitz, MD, FRCP, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Ionis; Janssen Pharmaceuticals; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Portola Pharmaceuticals, Inc.</p>

<p>Dr Weitz does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.</p>

<p>Dr Weitz does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.</p>
</td>
</tr>

</table>
<h2>
<a name="Heading501"></a><strong>SD/Editor/Writer Information and Disclosure Statements</strong></h2>
<p><strong><em>List in order as to appear on the site.</em></strong><em> Click </em><strong>+</strong><em> to add more</em></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p>Caroline M. Padbury, BPharm Lead Scientific Director, Medscape, LLC</p>

<p>Disclosure: Caroline M Padbury, BPharm, , has disclosed no relevant financial relationships.</p>
</td>
</tr>

</table>
<h2>
<a name="Heading506"></a><strong>Additional Planners/Reviewers Information and Disclosure Statements</strong></h2>
<p><strong><em>Select the appropriate CME reviewer involved in the project using the building block below.</em></strong><em> Click </em><strong>+</strong><em> to add more reviewers</em></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p></p>

<p><strong>CME Reviewer &#953;</strong></p>

<p>Nafeez Zawahir, MD CME Clinical Director, Medscape, LLC</p>

<p>Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.</p>

<p><strong>Peer Reviewer</strong></p>

<p>This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships: 
<br>    
Served as an advisor or consultant for: Abbott Laboratories; Medtronic, Inc.</p>
</td>
</tr>

</table>
<h1>
<a name="Heading517"></a><strong>References</strong></h1>
<p>1. Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. <em>J Clin Oncol</em>. 2015;33:654-656. </p>
<p>2. Cohen&#160;AT.&#160;Discoveries in thrombosis care for medical patients.&#160;<em>Semin Thromb Hemost</em>. 2002;28(suppl 3):13-17.</p>

<p>3. ClinicalTrials.gov. Apixaban for the prevention of venous thromboembolism in cancer patients (AVERT). https://clinicaltrials.gov/ct2/show/NCT02048865. Accessed August 23, 2018.</p>

<p>4. Khorana AA, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. <em>Thromb Haemost</em>. 2017;117:2135-2145. </p>

<p>5. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. <em>N Engl J Med.</em> 2018;378:615-624.</p>

<p>6. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). <em>J Clin Oncol</em>. 2018;36:2017-2023. </p>

<p>7. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. <em>N Engl J Med</em>. 2003;349:146-153.</p>

<p>8. Khorana AA, McCrae KR, Milentijevic D, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. <em>Res Pract Thromb Haemost</em>. 2017;1:14-22. </p>

<p>9. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. <em>Blood</em>. 2002;100:3484-3488. </p>

<p>10. Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer associated venous thromboembolism. <em>Circulation</em> 2012; 126: 448-454.</p>

<p>11. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. <em>J Thromb Haemost</em>. 2018. [Epub ahead of print]</p>

<p>12. Clinicaltrials.gov. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO)  https://clinicaltrials.gov/ct2/show/NCT03045406. Accessed August 23, 2018.</p>


</body>

</html>
